SI3218504T1 - Tri-segmentirani arenavirusi kot vakcinski vektorji - Google Patents
Tri-segmentirani arenavirusi kot vakcinski vektorjiInfo
- Publication number
- SI3218504T1 SI3218504T1 SI201531397T SI201531397T SI3218504T1 SI 3218504 T1 SI3218504 T1 SI 3218504T1 SI 201531397 T SI201531397 T SI 201531397T SI 201531397 T SI201531397 T SI 201531397T SI 3218504 T1 SI3218504 T1 SI 3218504T1
- Authority
- SI
- Slovenia
- Prior art keywords
- tri
- vaccine vectors
- arenaviruses
- segmented
- segmented arenaviruses
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10041—Use of virus, viral particle or viral elements as a vector
- C12N2760/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10061—Methods of inactivation or attenuation
- C12N2760/10062—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/80—Vectors comprising a special translation-regulating system from vertebrates
- C12N2840/85—Vectors comprising a special translation-regulating system from vertebrates mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462079493P | 2014-11-13 | 2014-11-13 | |
| PCT/EP2015/076458 WO2016075250A1 (en) | 2014-11-13 | 2015-11-12 | Tri-segmented arenaviruses as vaccine vectors |
| EP15794900.9A EP3218504B1 (en) | 2014-11-13 | 2015-11-12 | Tri-segmented arenaviruses as vaccine vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3218504T1 true SI3218504T1 (sl) | 2020-11-30 |
Family
ID=54545130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201531397T SI3218504T1 (sl) | 2014-11-13 | 2015-11-12 | Tri-segmentirani arenavirusi kot vakcinski vektorji |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10722564B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3778903A1 (cg-RX-API-DMAC7.html) |
| JP (4) | JP6805139B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN107223130A (cg-RX-API-DMAC7.html) |
| AU (3) | AU2015345080B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2967720C (cg-RX-API-DMAC7.html) |
| CY (1) | CY1123339T1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3218504T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2811093T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20201684T1 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE051390T2 (cg-RX-API-DMAC7.html) |
| LT (1) | LT3218504T (cg-RX-API-DMAC7.html) |
| PL (1) | PL3218504T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT3218504T (cg-RX-API-DMAC7.html) |
| RS (1) | RS60937B1 (cg-RX-API-DMAC7.html) |
| SI (1) | SI3218504T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016075250A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2604695T1 (sl) | 2007-12-27 | 2023-03-31 | Universitaet Zuerich Prorektorat Forschung | Replikacijsko defektni arenavirusni vektorji |
| ES2868427T3 (es) * | 2013-12-03 | 2021-10-21 | Hookipa Biotech Ag | Vacunas contra el CMV |
| CA2967720C (en) | 2014-11-13 | 2024-01-02 | Universite De Geneve | Tri-segmented arenaviruses as vaccine vectors |
| EP3307308A2 (en) * | 2015-06-10 | 2018-04-18 | Hookipa Biotech AG | Hpv vaccines |
| WO2018045029A1 (en) * | 2016-09-02 | 2018-03-08 | The United States Of America, As Represented By The Secretary Of The Army | Pan south american arenavirus live attenuated vaccine |
| HRP20221474T1 (hr) * | 2015-11-04 | 2023-01-06 | Hookipa Biotech Gmbh | Cjepiva protiv virusa hepatitisa b |
| SI3373959T1 (sl) | 2015-11-12 | 2022-11-30 | Hookipa Biotech Gmbh | Arenavirusni delci kot cepiva proti raku |
| US20200206334A1 (en) * | 2016-11-04 | 2020-07-02 | Hookipa Biotech Gmbh | Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines |
| AU2018247958A1 (en) * | 2017-04-07 | 2019-10-10 | Hookipa Biotech Gmbh | Arenavirus particles to treat solid tumors |
| US11021692B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Hepatitis B virus (HBV) vaccines and uses thereof |
| CN108611310A (zh) * | 2018-04-28 | 2018-10-02 | 中国药科大学 | 一种重组Hsp65与STEAP1186-193融合蛋白的基因工程菌的构建 |
| CN108977434A (zh) * | 2018-07-03 | 2018-12-11 | 张罗 | 鼻腔脱落细胞rna的提取方法 |
| AU2020297011A1 (en) * | 2019-06-18 | 2022-02-10 | Janssen Sciences Ireland Unlimited Company | Arenavirus vectors for hepatitis B virus (HBV) vaccines and uses thereof |
| JP7454645B2 (ja) | 2019-07-16 | 2024-03-22 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖワクチン並びにその作製方法及び使用方法 |
| IL315295A (en) | 2019-09-30 | 2024-10-01 | Gilead Sciences Inc | Hbv vaccines and methods treating hbv |
| WO2021089853A1 (en) | 2019-11-07 | 2021-05-14 | Universität Basel | Arenaviruses as vectors |
| EP4157342A1 (en) | 2020-05-29 | 2023-04-05 | Hookipa Biotech GmbH | Cancer treatment strategies using arenavirus vectors |
| JP7693813B2 (ja) | 2021-01-14 | 2025-06-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖワクチン及び使用方法 |
| WO2022159664A1 (en) * | 2021-01-22 | 2022-07-28 | Chan Zuckerberg Biohub, Inc. | Engineered multi-segmented rna viruses for large-scale combinatorial genetic screening |
| JP2024512566A (ja) | 2021-03-23 | 2024-03-19 | ホオキパ バイオテック ジーエムビーエイチ | 前立腺癌の治療に使用されるアレナウイルス |
| EP4337320A1 (en) | 2021-05-13 | 2024-03-20 | Hookipa Biotech GmbH | Arenaviruses as vectors |
| KR20240109607A (ko) | 2021-11-08 | 2024-07-11 | 후키파 바이오테크 게엠베하 | 암 면역요법으로서 변이 kras, 돌연변이된 암 유발 유전자, 또는 종양 연관 항원을 발현하는 변형된 아레나바이러스 입자 |
| CN114231562A (zh) * | 2021-12-15 | 2022-03-25 | 中国科学院武汉病毒研究所 | 一种表达荧光素酶基因的淋巴脉络丛脑膜炎病毒及其构建方法和应用 |
| US20250057931A1 (en) | 2022-02-08 | 2025-02-20 | Hookipa Biotech Gmbh | Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines |
| CA3259040A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | HIV Immunogenic Polypeptides and Vaccines and Their Uses |
| WO2025056782A1 (en) | 2023-09-15 | 2025-03-20 | Hookipa Biotech Gmbh | Arenavirus formulations, methods and uses thereof |
| WO2025191169A1 (en) | 2024-03-15 | 2025-09-18 | Hookipa Biotech Gmbh | Modified arenavirus particles expressing cancer testis antigens as cancer immunotherapies |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| US8158413B2 (en) * | 2005-10-17 | 2012-04-17 | Institut Pasteur | Lentiviral vector-based vaccine |
| ES2536426T3 (es) | 2006-03-23 | 2015-05-25 | Novartis Ag | Compuestos de imidazoquinoxalina como inmunomoduladores |
| US8063063B2 (en) | 2006-03-23 | 2011-11-22 | Novartis Ag | Immunopotentiating compounds |
| SI2604695T1 (sl) | 2007-12-27 | 2023-03-31 | Universitaet Zuerich Prorektorat Forschung | Replikacijsko defektni arenavirusni vektorji |
| GB201001726D0 (en) * | 2010-02-03 | 2010-03-24 | Univ St Andrews | Bunyavirus vaccine |
| WO2012162428A1 (en) | 2011-05-23 | 2012-11-29 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Prime-boost vaccination for viral infection |
| US9492526B2 (en) | 2012-01-24 | 2016-11-15 | Sanford Health | Polynucleotides for treating oncogenic viral polypeptide positive tumors |
| US9809801B2 (en) | 2013-03-15 | 2017-11-07 | Université De Genève | Anti-mycobacterial vaccines |
| GB201305361D0 (en) | 2013-03-25 | 2013-05-08 | Univ Edinburgh | Enhanced expression |
| ES2868427T3 (es) | 2013-12-03 | 2021-10-21 | Hookipa Biotech Ag | Vacunas contra el CMV |
| WO2015183895A1 (en) | 2014-05-27 | 2015-12-03 | University Of Rochester | Novel arenavirus vaccine |
| US9943585B2 (en) | 2014-07-30 | 2018-04-17 | University Of Rochester | Methods and compositions related to reorganization of arenavirus genome for development of novel arenavirus live-attenuated vaccines (LAV) |
| CN107109371A (zh) | 2014-09-22 | 2017-08-29 | 明尼苏达大学评议会 | 皮钦德病毒反向遗传学系统及其使用方法 |
| GB201419572D0 (en) | 2014-11-03 | 2014-12-17 | Pirbright Inst The | Virus |
| CA2967720C (en) | 2014-11-13 | 2024-01-02 | Universite De Geneve | Tri-segmented arenaviruses as vaccine vectors |
| DE102015207036A1 (de) | 2015-04-17 | 2016-10-20 | Karl Sebastian Lang | Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften |
| EP3307308A2 (en) | 2015-06-10 | 2018-04-18 | Hookipa Biotech AG | Hpv vaccines |
| ES3021881T3 (en) | 2015-10-23 | 2025-05-27 | Pasteur Institut | Recombinant mopeia virus and vaccine platform |
| HRP20221474T1 (hr) * | 2015-11-04 | 2023-01-06 | Hookipa Biotech Gmbh | Cjepiva protiv virusa hepatitisa b |
| SI3373959T1 (sl) | 2015-11-12 | 2022-11-30 | Hookipa Biotech Gmbh | Arenavirusni delci kot cepiva proti raku |
| KR20240095333A (ko) | 2016-05-18 | 2024-06-25 | 유니버시타트 바셀 | 백신 벡터로서 3개의 세그먼트를 가진 피친드 바이러스 |
| US20200206334A1 (en) | 2016-11-04 | 2020-07-02 | Hookipa Biotech Gmbh | Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines |
| AU2018247958A1 (en) | 2017-04-07 | 2019-10-10 | Hookipa Biotech Gmbh | Arenavirus particles to treat solid tumors |
-
2015
- 2015-11-12 CA CA2967720A patent/CA2967720C/en active Active
- 2015-11-12 US US15/526,211 patent/US10722564B2/en active Active
- 2015-11-12 EP EP20184468.5A patent/EP3778903A1/en active Pending
- 2015-11-12 CN CN201580073235.6A patent/CN107223130A/zh active Pending
- 2015-11-12 HU HUE15794900A patent/HUE051390T2/hu unknown
- 2015-11-12 SI SI201531397T patent/SI3218504T1/sl unknown
- 2015-11-12 HR HRP20201684TT patent/HRP20201684T1/hr unknown
- 2015-11-12 PL PL15794900T patent/PL3218504T3/pl unknown
- 2015-11-12 RS RS20201251A patent/RS60937B1/sr unknown
- 2015-11-12 PT PT157949009T patent/PT3218504T/pt unknown
- 2015-11-12 ES ES15794900T patent/ES2811093T3/es active Active
- 2015-11-12 LT LTEP15794900.9T patent/LT3218504T/lt unknown
- 2015-11-12 AU AU2015345080A patent/AU2015345080B2/en active Active
- 2015-11-12 WO PCT/EP2015/076458 patent/WO2016075250A1/en not_active Ceased
- 2015-11-12 JP JP2017525893A patent/JP6805139B2/ja active Active
- 2015-11-12 EP EP15794900.9A patent/EP3218504B1/en active Active
- 2015-11-12 DK DK15794900.9T patent/DK3218504T3/da active
-
2020
- 2020-07-07 US US16/922,489 patent/US20210145950A1/en not_active Abandoned
- 2020-09-16 CY CY20201100879T patent/CY1123339T1/el unknown
- 2020-12-03 JP JP2020201083A patent/JP2021045154A/ja active Pending
-
2022
- 2022-01-06 AU AU2022200061A patent/AU2022200061A1/en not_active Abandoned
-
2023
- 2023-01-05 JP JP2023000345A patent/JP2023036933A/ja active Pending
- 2023-11-13 US US18/507,584 patent/US20240082376A1/en active Pending
-
2024
- 2024-11-06 AU AU2024259760A patent/AU2024259760A1/en active Pending
-
2025
- 2025-08-21 JP JP2025138430A patent/JP2025170342A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240082376A1 (en) | 2024-03-14 |
| PL3218504T3 (pl) | 2021-02-08 |
| US20170319673A1 (en) | 2017-11-09 |
| HK1244034A1 (en) | 2018-07-27 |
| ES2811093T3 (es) | 2021-03-10 |
| JP2023036933A (ja) | 2023-03-14 |
| LT3218504T (lt) | 2020-09-10 |
| JP2021045154A (ja) | 2021-03-25 |
| AU2015345080B2 (en) | 2022-01-27 |
| JP6805139B2 (ja) | 2020-12-23 |
| CA2967720C (en) | 2024-01-02 |
| WO2016075250A1 (en) | 2016-05-19 |
| AU2024259760A1 (en) | 2024-11-28 |
| CY1123339T1 (el) | 2021-12-31 |
| EP3218504B1 (en) | 2020-07-22 |
| DK3218504T3 (da) | 2020-10-19 |
| CA2967720A1 (en) | 2016-05-19 |
| US10722564B2 (en) | 2020-07-28 |
| AU2022200061A1 (en) | 2022-02-03 |
| PT3218504T (pt) | 2020-09-24 |
| RS60937B1 (sr) | 2020-11-30 |
| JP2017535267A (ja) | 2017-11-30 |
| US20210145950A1 (en) | 2021-05-20 |
| HRP20201684T1 (hr) | 2020-12-25 |
| EP3218504A1 (en) | 2017-09-20 |
| JP2025170342A (ja) | 2025-11-18 |
| AU2015345080A1 (en) | 2017-06-01 |
| CN107223130A (zh) | 2017-09-29 |
| EP3778903A1 (en) | 2021-02-17 |
| HUE051390T2 (hu) | 2021-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3218504T3 (pl) | Trójsegmentowe arenawirusy jako wektory szczepionkowe | |
| GB201410971D0 (en) | Vaccine | |
| GB201403684D0 (en) | Vector | |
| PT3207053T (pt) | Novos péptidos imunogénicos | |
| GB201517022D0 (en) | No details | |
| GB201518684D0 (en) | Vaccine | |
| GB201519531D0 (en) | No details | |
| PL3185899T3 (pl) | Wzmocniona szczepionka wektorowa-hvt przeciwko nd-ibd | |
| GB201418217D0 (en) | No details | |
| GB201509578D0 (en) | Vectors | |
| GB201418216D0 (en) | No details | |
| IL248223B (en) | Compositions of vaccine | |
| GB201517412D0 (en) | No details | |
| GB201517574D0 (en) | No details | |
| GB201522132D0 (en) | Vaccine | |
| PL3237349T3 (pl) | Ulepszony biologiczny środek wiążący | |
| GB201616904D0 (en) | Vaccine | |
| IL247535A0 (en) | Fox-viral oncolytic vectors | |
| GB201601250D0 (en) | No details present | |
| GB201503483D0 (en) | Novel Antimmicrobial Peptides | |
| GB201517605D0 (en) | No details | |
| SI3188755T1 (sl) | Cepivo | |
| GB201410910D0 (en) | No details | |
| ZA201702925B (en) | New immunostimulatory compounds | |
| GB201603029D0 (en) | Vaccine |